Drugs / RO5429083
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01641250 | Aug 2012 → Feb 2015 | acute myeloid leukemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01358903 | Jun 2011 → Mar 2014 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO5429083 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01358903 ↗ |
| Known as | RG 7356 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594601 ↗ |
| Route | Intravenous | “receive RO5429083 intravenously at escalating doses” NCT01358903 ↗ |